Monopar Therapeutics' stock (NASDAQ: MNPR) surged due to a licensing deal with Alexion for a promising drug to treat Wilson Disease. MNPR also showed positive results in its pipeline. The stock corrected from $32 to $17.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing